We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,361

Intellectual property issues of biomedical outsourcing in the PRC
  • King & Wood Mallesons
  • China
  • September 12 2012

As a result of the development of the biomedical industry and the Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) business models, China has become one of the most important outsourcing destination countries, acquiring considerable market share of the global outsourcing market

USPTO to host medical device technology partnership meeting
  • Shook Hardy & Bacon LLP
  • USA
  • November 17 2011

The U.S. Patent and Trademark Office (USPTO) has scheduled a November 29, 2011, meeting in Alexandria, Virginia, to bring together industry stakeholders and patent examiners and directors “to share ideas, experiences, and insights on best practices in advancing prosecution and provide a forum for discussion on how the agency can improve and expand its relationship with the medical device technology community.”

China and the United States convene 22nd session of JCCT
  • White & Case LLP
  • China, USA
  • January 10 2012

On November 20 21, 2011, Chinese Vice Premier Wang Qishan, US Secretary of Commerce John Bryson and US Trade Representative Ron Kirk, co-chaired the 22nd session of the Joint Commission on Commerce and Trade meeting in Chengdu, China

Bric-a-brac: January 31, 2014
  • Michael Best & Friedrich LLP
  • Nigeria, Russia, USA
  • January 31 2014

An interesting article in Pharmaexec.com discusses Russia's focus on developing a "world class" biopharmaceutical sector. The article states that

Patent term and double dipping
  • Baker & Hostetler LLP
  • USA
  • February 1 2009

Pharmaceutical companies have dreamed up numerous strategies to forestall the loss of profits when a patent expires

Pharmaceutical patents in Italy: hot topics
  • Avvocati Associati Franzosi Dal Negro Setti
  • Italy
  • February 1 2009

Timely issues preoccupying pharmaceutical patent owners in Italy include the duration of supplementary protection certificates, the extent of the Bolar exemption and the recovery of damages for infringement

The best of both worlds?
  • LK Shields
  • Ireland
  • July 31 2012

In the field of pharmaceuticals and biotechnology, collaboration agreements are increasingly being used to get products from pipeline to target market in the most cost-effective way

Follow-on biologics: a patent litigation perspective
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • August 22 2009

In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully

Data protection in Canada: too much? Too little?
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 28 2011

Prior to the enactment in 2006 of the amendments to section C.08.004.1 of the Food and Drugs Regulations (Data Protection Regulations), Canada did not have an effective regime of data protection exclusivity

FTC continues to fight controversial reverse payments
  • Hogan Lovells
  • USA
  • October 27 2011

Over the past few years the Federal Trade Commission has placed a high priority on reining in pharmaceutical litigation settlements that involve payments from the branded company to the generic company, together with an agreed date for generic entry